Menopause Age and Anxiety-Depression

Menopause is defined as the permanent cessation of menstrual cycles due to ovarian follicle depletion, typically occurring after age 50, and is associated with decreased estrogen levels. Primary ovarian insufficiency (POI) involves early ovarian dysfunction before age 40, with infertility as a key concern. Both menopause and POI may contribute to psychological symptoms, including anxiety and depression, influenced by sociodemographic and health factors. While literature reports anxiety in middle-aged women, data on its association with menopausal timing are limited. This study aims to compare women with POI and those undergoing natural menopause after age 40, assessing the relationship between age at menopause, anxiety, and depression, as well as the impact of fertility expectations on psychological well-being in POI patients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Menopause Adnexal Diseases Anxiety Anxiety Disorders Behavior Behavioral Symptoms Depression Endocrine System Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genital Diseases Genital Diseases, Female Gonadal Disorders Menopausal Depression Mental Disorders Ovarian Diseases Primary Ovarian Insufficiency Primary Ovarian Insufficiency (Poi) Urogenital Diseases

Age range

24 year and older

Sex eligibility

Female

Study type

Observational

Primary location

Ankara Bilkent City Hospital

Ankara, Not Valid, 06100, Turkey (Türkiye)

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Healthy women over 24 years of age who visited our hospital for routine outpatient check-ups, had been diagnosed with menopause, and had no history of psychiatric disorders before menopause.

Exclusion criteria

Cardiovascular diseases including hypertension
Type 1 or type 2 diabetes mellitus
Morbid obesity
Primary adrenal insufficiency
Uterine fibroids
Thyroid dysfunctions including Hashimoto thyroiditis and Grave's disease
Hepatic dysfunctions
Renal insufficiency
Genetic disorders in chromosome constitution or karyotype analysis including monosomy X, trisomy X and gene mutations as BMP15, FMR I, POFIB, and GDF9
Neurologic diseases
Psychiatric disorders
Autoimmune diseases or syndromes including Addison's disease, autoimmune syndromes, scleroderma, Sjogren's syndrome, myasthenia gravis, inflammatory bowel diseases, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus and familial Mediterranean fever
History of any malignancy
History of exposure to chemotherapeutic agents or radiotherapy
Individuals with a history of chronic or regular medication use that could cause anxiety or depression symptoms
Individuals with a personal history of psychiatric disorders
Individuals with a history of depression in the past 6 months.

Treatment and study plan

Beck Anxıety Inventory (BAI)

Other

Beck Anxıety Inventory (BAI) Description: The scale will be self-administered and completed by the patient during the routine outpatient clinic visit.

Other names: State-Trait Anxiety Scale (STAI) 1-2

State-Trait Anxiety Scale (STAI) 1-2

Other

State-Trait Anxiety Scale (STAI) 1-2 Description: The scale will be self-administered and completed by the patient during the routine outpatient clinic visit.

Primary outcomes

Beck Anxıety Inventory (BAI), Anxiety level

Time frame: Baseline (single assessment at enrollment during routine clinic visit).

Anxiety severity measured by the Beck Anxiety Inventory (BAI) during routine clinic visit.
State-Trait Anxiety Scale (STAI) 1-2, Anxiety level

Time frame: Baseline (single assessment at enrollment during routine clinic visit).

Anxiety severity measured by the State-Trait Anxiety Inventory (STAI) forms 1 and 2 during routine clinic visit.

Sponsors and collaborators

Lead sponsor

Ankara City Hospital Bilkent

Other

Registry information

Official study title

Association Between Age at Menopause and Levels of Anxiety and Depression

Important dates

Study start: 2024
Primary completion: 2025
Study completion: 2025
First posted: Dec 19, 2025
Registry last updated: Dec 19, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed